A recent report says that FDA inspections of Indian drugmakers tripled between 2010 and 2015, and that trend continues this year, with the latest to feel the…

FDA inspectors continue to roll through Dr. Reddy’s plants in India and continue to find issues along the way.

Two months after snapping up Ariad, Takeda is getting a quick return. The Ariad-developed potential blockbuster Alunbrig won FDA approval Friday.

Novartis is learning about its kickbacks punishment in South Korea as authorities decided to issue a fine of nearly $50 million.

The FDA, which banned APIs coming from a Divi’s plant in India, has followed that with a warning letter that savages the facility for a lack of data integrity.

For nearly two years Teva struggled with impurity issues for an API manufactured at a plant in China.

Sun Pharma has had another setback in its manufacturing for the U.S. market with the FDA laying out nearly a dozen observations for a solid dose formulation…

The FDA issued Aurobindo Pharma a Form 483, citing six observations related to procedural improvements at the company’s Unit III facility at Bachupally in…

The FDA has nailed another Teva manufacturing facility with a warning letter, this time for an API facility in China.